MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13045-020-00855-9

Медицинская библиотека · Journal of hematology & oncology · 2020

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.

Yoon Dok Hyun, Cao Junning, Chen Tsai-Yun, Izutsu Koji, Kim Seok Jin, Kwong Yok Lam, Lin Tong Yu, Thye Lim Soon, Xu Bing, Yang Deok Hwan, Kim Won Seog

СтатьяПоддержка исследования: вне правительства СШАОбзорConsensus StatementПеревод пока не подготовлен

Аннотация

BACKGROUND

Mantle cell lymphoma (MCL) is a B cell malignancy that can be aggressive and with a poor prognosis; the clinical course is heterogeneous. The epidemiology of MCL in Asia is not well documented but appears to comprise 2-6% of all lymphoma cases based on available data, with variation observed between countries. Although international guidelines are available for the treatment of MCL, there is a lack of published data or guidance on the clinical characteristics and management of MCL in patient populations from Asia. This paper aims to review the available treatment and, where clinical gaps exist, provide expert consensus from the Asian Lymphoma Study Group (ALSG) on appropriate MCL management in Asia. BODY: Management strategies for MCL are patient- and disease stage-specific and aim to achieve balance between efficacy outcomes and toxicity. For asymptomatic patients with clearly indolent disease, observation may be an appropriate strategy. For stage I/II disease, following international guidelines is appropriate, which include either a short course of conventional chemotherapy followed by consolidated radiotherapy, less aggressive chemotherapy regimens, or a combination of these approaches. For advanced disease, the approach is based on the age and fitness of the patient. For young, fit patients, the current practice for induction therapy differs across Asia, with cytarabine having an important role in this setting. Hematopoietic stem cell transplantation (HSCT) may be justified in selected patients because of the high relapse risk. In elderly patients, specific chemoimmunotherapy regimens available in each country/region are a treatment option. For maintenance therapy after first-line treatment, the choice of approach should be individualized, with cost being an important consideration within Asia. For relapsed/refractory disease, ibrutinib should be considered as well as other follow-on compounds, if available.

CONCLUSION

Asian patient-specific data for the treatment of MCL are lacking, and the availability of treatment options differs between country/region within Asia. Therefore, there is no clear one-size-fits-all approach and further investigation on the most appropriate sequence of treatment that should be considered for this heterogeneous disease.

Для цитирования: Yoon Dok Hyun, Cao Junning, Chen Tsai-Yun, Izutsu Koji, Kim Seok Jin, Kwong Yok Lam, Lin Tong Yu, Thye Lim Soon, Xu Bing, Yang Deok Hwan, Kim Won Seog. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.. Journal of hematology & oncology. 2020. DOI: 10.1186/s13045-020-00855-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.